Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Thejew on Jun 01, 2020 6:26pm
623 Views
Post# 31098777

Wallace is a legend, Dan sucks.

Wallace is a legend, Dan sucks.

After taking some time to reflect on results and blow off some steam, I have a few thoughts. As usual, I am blown away by the science here. But Dan has always been my least favorite thing about this stock. Todays release was totally unprofessional, especially considering the circumstances.

For starters they obviously should have halted the stock before opening, standard practice when releasing big results such as these. That way you eliminate knee jerk reactions, which is what happened today. Then results can be delved into more thoroughly. Once unhalted, they should have had a conference call with the new CMO, the CEO and the man himself Dr. Wallace to give a breakdown of the results and answer questions and clear up any issues, which obviously there are quite a few (no womacs, funding, LTE, etc)

To those who say have patience, kudos to you I guess. I have been in here, with almost half my portfolio at one point, for two years. And shareholders have patiently waited through delay after delay....only for years of hard work to come out with a lackluster PR and the stock to tank.

And on top of all that they didn't even thank the shareholders LOL....We're the ones that funded everything with our hard earned money and patiently waited for years for this. I'm still bullish on the science, but my confidence in Dan is zero. This is above his paygrade IMO. He doesn't have enough experience in the markets to be CEO (he was a pilot, lawyer, etc and probably landed the job because him and Wallace are old college buddies).

Bullboard Posts